Promising cancer combo trial pulled before it even started

NCT ID NCT05668949

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test whether adding an experimental drug called TTI-101 to the immunotherapy pembrolizumab (Keytruda) is safe and effective for people with head and neck cancer that has returned or spread. The trial was withdrawn before enrolling any participants, so no data were collected. It would have included people who had not previously received certain immunotherapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TTI-101 and pembrolizumab (Keytruda)
What this could lead to: If this combination had been tested and worked, it could have pointed toward a new treatment option for people with head and neck cancer that has come back or spread.
What could go wrong: The trial was withdrawn before enrolling anyone, so no results are available. Even if it had run, it was an early-phase study with a small number of participants, so success was uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.